within Pharmacolibrary.Drugs.ATC.L;

model L01CA04_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 7.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005833333333333334,
    Tlag           = 1200,            
    Vdp             = 0.01523,
    k12             = 2.9,
    k21             = 2.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01CA04_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vinorelbine is a semi-synthetic vinca alkaloid antineoplastic agent primarily used for treatment of non-small cell lung cancer and metastatic breast cancer.</p><h4>Pharmacokinetics</h4><p>Oral vinorelbine pharmacokinetics in adult cancer patients; values based on clinical studies with oral administration. Bioavailability is less than intravenous.</p><h4>References</h4><ol><li><p>Hamimed, M, et al., &amp; Leblond, P (2022). Pharmacokinetics of oral vinorelbine in French children with recurrent or progressive primary low-grade glioma. <i>British journal of clinical pharmacology</i> 88(5) 2096–2117. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15131&quot;>10.1111/bcp.15131</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34709655/&quot;>https://pubmed.ncbi.nlm.nih.gov/34709655</a></p></li><li><p>Marty, M, et al., &amp; Puozzo, C (2001). Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 12(11) 1643–1649. DOI:<a href=&quot;https://doi.org/10.1023/a:1013180903805&quot;>10.1023/a:1013180903805</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11822766/&quot;>https://pubmed.ncbi.nlm.nih.gov/11822766</a></p></li><li><p>Yang, Y, et al., &amp; Zhang, L (2019). A randomised, multicentre open-label phase II study to evaluate the efficacy, tolerability and pharmacokinetics of oral vinorelbine plus cisplatin versus intravenous vinorelbine plus cisplatin in Chinese patients with chemotherapy-naive unresectable or metastatic non-small cell lung cancer. <i>Journal of thoracic disease</i> 11(8) 3347–3359. DOI:<a href=&quot;https://doi.org/10.21037/jtd.2019.08.22&quot;>10.21037/jtd.2019.08.22</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31559038/&quot;>https://pubmed.ncbi.nlm.nih.gov/31559038</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01CA04_1;
